References
- Sabbadin C, Calò LA, Armanini D. The story of spironolactones from1957 to now: from sodium balance to inflammation. G Ital Nefrol. 2016;33(S66):33.S66.12.
- Armanini D, Karbowiak I, Goi A, et al. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf). 1985;23(4):341–347.
- Armanini D, Sabbadin C, Donà G, et al. Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opin Pharmacother. 2014;15(7):909–912.
- Sabbadin C, Armanini D. Syndromes that mimic an excess of mineralocorticoids. High Blood Press Cardiovasc Prev. 2016. [Epub ahead of print]. doi:10.1007/s40292-016-0160-5.
- Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab. 1980;51(3):429–432.
- Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85(1):89–94.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
- Karaer A, Cavkaytar S, Mert I, et al. Cardiovascular risk factors in polycystic ovary syndrome. J Obstet Gynaecol. 2010;30(4):387–392.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.
- Armanini D, Bordin L, Donà G, et al. Polycystic ovary syndrome: implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids. 2012;77:655–658.
- Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol. 1985;248:E388–E390.
- Calò LA, Zaghetto F, Pagnin E, et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab. 2004;89:1973–1976.
- Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717.
- Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
- Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005;28(1):49–53.
- Sabbadin C, Andrisani A, Zermiani M, et al. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Invest. 2016. Epub 2016 Apr 12. [Epub ahead of print]. doi:10.1007/s40618-016-0466-0.
- Armanini D, Fiore C, Pellati D. Spontaneous resolution of idiopathic aldosteronism after long-term treatment with potassium canrenoate. Hypertension. 2007;50(4):e69–e70.
- Armanini D, Castello R, Scaroni C, et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol. 2007;131(1):61–67.